check_circleStudy Completed
Osteoporosis, postmenopausal
Bayer Identifier:
15075
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Julina post-marketing surveillance for postmenopausal osteoporosis in Japan
Trial purpose
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Julina for postmenopausal osteoporosis. The objective of this study is to assess safety and efficacy of using Julina in clinical practice. A total 100 patients will be recruited and followed 3 years since starting Julina administration.
Key Participants Requirements
Sex
FemaleAge
0 - N/ATrial summary
Enrollment Goal
148Trial Dates
January 2009 - April 2014Phase
N/ACould I Receive a placebo
NoProducts
Julina (Estradiol, BAY86-5435)Accepts Healthy Volunteer
NoWhere to participate
Status | Institution | Location |
---|---|---|
Completed | Many Locations, Japan |
Primary Outcome
- Incidence of adverse drug reactions and serious adverse events in subject who received Julinadate_rangeTime Frame:After Julina administration, upto 3 yearsenhanced_encryptionYesSafety Issue:
Secondary Outcome
- Incidence of adverse drug reactions in subpopulation with baseline data (such as demographic data, concomitant disease, hysterectomy) and dose of Julinadate_rangeTime Frame:At baseline and after Julina administration, upto 3 yearsenhanced_encryptionYesSafety Issue:
- Effectiveness evaluation assessment by the three rank scales: improvement, not changed, and worsedate_rangeTime Frame:At baseline and at end of Julina treatment, upto 3 yearsenhanced_encryptionNoSafety Issue:
Trial design
Trial Type
ObservationalIntervention Type
DrugTrial Purpose
N/AAllocation
N/ABlinding
N/AAssignment
N/ATrial Arms
N/A